12 October 2016 - HAS has published the agenda for the next scheduled Transparency Commission meeting.

The Commission will consider the reimbursement of the following technologies:

• Daclizumab (Daklinza)
  
• Pixantrone dimaleate (Pixuvri)
• House dust mite allergen extract (Acarizax)
• Sofosbuvir with velpatasvir (Epclusa)
• Grazoprevir with elbasvir (Zepatier)
• Susoctocog alfa (Obizur)
  

Read agenda for 19 October meeting [French]